Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ATP4A | P20648 | 2/20 | 0.47 |
| ▸ | ATP4B | P51164 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 3/20 | 0.43 |
| ▸ | CDC25B | P30305 | 2/20 | 0.43 |
| ▸ | CDC25C | P30307 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14318199 | 0.89 | MAPT (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14315463 | 0.89 | ATP4A (0.52) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14224930 | 0.88 | MAPT (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL16404020 | 0.88 | ATP4A (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| Milpecitinib SCHEMBL14224928 | 0.88 | ATP4A (0.52) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14224927 | 0.87 | JAK3 (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| Milpecitinib SCHEMBL14150553 | 0.87 | ATP4A (0.52) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14224901 | 0.86 | MAPT (0.49) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14150274 | 0.85 | JAK3 (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL14318313 | 0.84 | JAK3 (0.51) | SMN1; SMN2MAPTHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718290-B1 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | CLEVEXEL PHARMA (FR) | 2016-05-04 | — | — | EP | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| WO-2012172438-A9 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012172438-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-12-20 | — | — | WO | disclosed |
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | PRKCH, MAP3K2, MAP3K6 | SMN1; SMN2 3668/4885MAPT 2739/4885HTT 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.